Amedisys, Inc. (NASDAQ:AMED - Free Report) - Stock analysts at William Blair raised their Q2 2024 EPS estimates for Amedisys in a research report issued to clients and investors on Thursday, April 25th. William Blair analyst M. Larew now expects that the health services provider will post earnings of $1.18 per share for the quarter, up from their prior forecast of $1.04. The consensus estimate for Amedisys' current full-year earnings is $4.54 per share. William Blair also issued estimates for Amedisys' Q3 2024 earnings at $1.12 EPS and Q4 2024 earnings at $1.21 EPS.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, April 24th. The health services provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $571.41 million for the quarter, compared to the consensus estimate of $565.38 million. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The business's quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.00 earnings per share.
Other equities analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday. Raymond James reissued a "market perform" rating on shares of Amedisys in a research report on Tuesday, March 26th. Royal Bank of Canada upped their target price on Amedisys from $97.00 to $100.00 and gave the company an "outperform" rating in a research report on Monday, March 25th. Finally, StockNews.com started coverage on Amedisys in a research report on Monday, April 8th. They issued a "buy" rating on the stock. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $97.50.
View Our Latest Stock Analysis on AMED
Amedisys Stock Up 0.7 %
Shares of AMED stock traded up $0.63 during trading hours on Friday, reaching $91.79. 144,548 shares of the company's stock were exchanged, compared to its average volume of 276,231. The stock's 50 day moving average is $92.57 and its 200-day moving average is $93.35. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -142.84, a P/E/G ratio of 4.28 and a beta of 0.86. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys has a fifty-two week low of $73.10 and a fifty-two week high of $96.44.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC raised its position in shares of Amedisys by 2.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 3,896 shares of the health services provider's stock worth $364,000 after purchasing an additional 110 shares during the last quarter. Xponance Inc. raised its holdings in Amedisys by 3.2% in the 3rd quarter. Xponance Inc. now owns 4,076 shares of the health services provider's stock valued at $381,000 after acquiring an additional 125 shares during the last quarter. Retirement Systems of Alabama raised its holdings in Amedisys by 0.3% in the 4th quarter. Retirement Systems of Alabama now owns 40,871 shares of the health services provider's stock valued at $3,885,000 after acquiring an additional 125 shares during the last quarter. Treasurer of the State of North Carolina raised its holdings in Amedisys by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 14,204 shares of the health services provider's stock valued at $1,350,000 after acquiring an additional 140 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in Amedisys by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 9,284 shares of the health services provider's stock valued at $867,000 after acquiring an additional 141 shares during the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.
About Amedisys
(
Get Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Recommended Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
